Evidence map›Paper›PMID 34990570›Full record

ArticleCancer cell2022

Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer.

Vivek Naranbhai, Kerri J St Denis, Evan C Lam, Onosereme Ofoman, Wilfredo F Garcia-Beltran, Cristhian B Mairena, Atul K Bhan, Justin F Gainor, Alejandro B Balazs, A John Iafrate and 1 more

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
3.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Mechanistic model for booster doses effectiveness in healthy, cancer, and immunosuppressed patients infected with SARS-CoV-2.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  15. Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023
    Review
  16. Observational
  17. Article
  18. Review
  19. The Interplay of Lung Cancer, COVID-19, and Vaccines.International journal of molecular sciences · 2022
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Vivek NaranbhaiMassachusetts General Hospital Cancer Center, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA; Dana-Farber Cancer Institute, Boston, MA, USA; Center for the AIDS Programme of Research in South Africa, Durban, South Africa.
Kerri J St DenisRagon Institute of MGH, MIT and Harvard, Boston, MA, USA.
Evan C LamRagon Institute of MGH, MIT and Harvard, Boston, MA, USA.
Onosereme OfomanDepartment of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Wilfredo F Garcia-BeltranRagon Institute of MGH, MIT and Harvard, Boston, MA, USA; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Cristhian B MairenaDepartment of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Atul K BhanDepartment of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Justin F GainorMassachusetts General Hospital Cancer Center, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.
Alejandro B BalazsRagon Institute of MGH, MIT and Harvard, Boston, MA, USA.
A John IafrateMassachusetts General Hospital Cancer Center, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA. Electronic address: aiafrate@partners.org.
CANVAX team
Massachusetts General Hospital · USRagon Institute of MGH, MIT and Harvard · USCentre for the AIDS Programme of Research in South Africa · ZA

Funding

Engineering Humoral Immunity to Functionally Cure HIV InfectionDP2DA040254 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI BALAZS, ALEJANDRO BENJAMIN · 2015 to 2015
$2.6M
NIDA NIH HHS DP2 DA040254
6 · The paper itself

Abstract

Patients with cancer are more likely to have impaired immune responses to SARS-CoV-2 vaccines. We study the breadth of responses against SARS-CoV-2 variants after primary vaccination in 178 patients with a variety of tumor types and after booster doses in a subset. Neutralization of alpha, beta, gamma, and delta SARS-CoV-2 variants is impaired relative to wildtype, regardless of vaccine type. Regardless of viral variant, mRNA1273 is the most immunogenic, followed by BNT162b2, and then Ad26.COV2.S. Neutralization of more variants (breadth) is associated with a greater magnitude of wildtype neutralization, and increases with time since vaccination; advancing age associates with a lower breadth. The concentrations of anti-spike protein antibody are a good surrogate for breadth (positive predictive value of =90% at >1,000 U/mL). Booster SARS-CoV-2 vaccines confer enhanced breadth. These data suggest that achieving a high antibody titer is desirable to achieve broad neutralization; a single booster dose with the current vaccines increases the breadth of responses against variants.

Indexed as

AgedAgingAntibodies, NeutralizingAntibodies, ViralAntigens, ViralCOVID-19COVID-19 VaccinesFemaleHumansImmunization, SecondaryImmunocompromised HostImmunogenicity, VaccineIn Vitro TechniquesMaleMiddle AgedNeoplasmsAntibodies, NeutralizingAntibodies, ViralAntigens, ViralCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Ad26.COV2.SBNT162b2booster dosebreadthcancermRNA1273neutralizationSARS-CoV-2variants

Identifiers

PMID34990570
PMCPMC8730528
OpenAlexW4225544422

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.